Research Paper Volume 14, Issue 16 pp 6467—6480

Effect of BBT-877, a novel inhibitor of ATX, on a mouse model of type 1 diabetic nephropathy

class="figure-viewer-img"

Figure 4. BBT-877 reduces the protein levels of fibrotic factors in STZ-induced diabetic mice. After treatment with BBT-877 for 8 weeks, mice were sacrificed and their kidneys were collected. Protein was extracted and subjected to western blotting for (A) TGF-β, (B) Fibronectin, (C) CTGF, and (D) COL1A1. Abbreviations: STZ: streptozotocin; qRT-PCR: quantitative reverse transcriptase-polymerase chain reaction. STZ-10BBT: BBT-877 10 mg/kg, STZ-30BBT: BBT-877 30 mg/kg, STZ-90BBT: BBT-877 90 mg/kg, STZ-10L: losartan 10 mg/kg. *p < 0.05, control-vehicle vs. STZ-vehicle, #p < 0.05, STZ-vehicle vs. STZ-10, 30, 90BBT or STZ-10L, n = 8−10.